COLOFAC

This brand name is authorized in Australia, Austria, Ireland, Malta, New Zealand, South Africa, UK.

Active ingredients

The drug COLOFAC contains one active pharmaceutical ingredient (API):

1	Mebeverine UNII 15VZ5AL4JN - MEBEVERINE HYDROCHLORIDE
	Mebeverine is a musculotropic antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility.
	Read more about Mebeverine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COLOFAC Coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
COLOFAC Modified release capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A03AA04	Mebeverine	A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AA Synthetic anticholinergics, esters with tertiary amino group
Discover more medicines within A03AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4328T
GB	Medicines & Healthcare Products Regulatory Agency	138550, 142076, 175359, 175360, 22224, 29022, 29091, 373865
IE	Health Products Regulatory Authority	17795, 76139
MT	Medicines Authority	MA1507/00101, PI1438/04801A, PI908/01201B
NZ	Medicines and Medical Devices Safety Authority	809
ZA	Health Products Regulatory Authority	Q/11.2/165